Which disease-relevant molecular pathways and gene-network modules most plausibly drive Systemic lupus erythematosus initiation and progression, and what causal experiments (e.g., perturbation, single

Systemic lupus erythematosus (SLE) initiation and progression are driven by a complex interplay of type I interferon (IFN) hyperactivation, nucleic acid sensing dysregulation, and aberrant B-cell and macrophage maturation (PMID: 38420886, PMID: 41648138). Pathogenic progression is marked by the expansion of specific immune subsets, such as age-associated B cells (ABCs) and pro-inflammatory S100+ monocytes, which infiltrate target organs like the kidneys and skin (PMID: 41593131, PMID: 41490945).

Disease-Relevant Molecular Pathways and Gene-Network Modules

1. Type I Interferon (IFN) Signaling and Nucleic Acid Sensing

The "interferon signature" is the primary driver of SLE pathogenesis (PMID: 12604793). Overactivation occurs through three dominant mechanisms:
* Defective Nucleic Acid Metabolism: Loss-of-function (LoF) variants in genes such as DNASE1L3, TREX1, and SAMHD1 prevent the clearance of apoptotic debris and neutrophil extracellular traps (NETs), leading to the accumulation of self-nucleic acids (PMID: 38420886, PMID: 41596602).
* Constitutive Sensor Activation: Gain-of-function (GoF) variants in TLR7 and IFIH1 (MDA5) lower the threshold for sensing RNA/DNA, promoting a B-cell-intrinsic breach in tolerance (PMID: 38420886, PMID: 41596733).
* Gene-Network Hubs: Integrated bioinformatics has identified a 10-gene interferon-centered hub (STAT1, IRF7, OAS1, OAS2, ISG15, MX2, IFI35, RSAD2, SAMD9, SAMD9L) that consistently differentiates SLE patients from healthy controls and tracks with disease activity (PMID: 41569989).

2. B-Cell Dysregulation and Plasmablast Expansion

B-cells drive progression through autoantibody production and antigen presentation (PMID: 37165096).
* Extrafollicular (EF) Circuitry: SLE is characterized by an expansion of DN2 B cells (T-bet+ CD11c+ CXCR5-) and plasmablasts (PMID: 41597194). These cells are generated via an IFN-driven extrafollicular pathway that bypasses traditional germinal center checkpoints (PMID: 41583477).
* B-cell Receptor (BCR) Signaling: Variants in BLK, BANK1, and PTPN22 alter BCR signaling thresholds, allowing autoreactive B cells to survive and differentiate (PMID: 31385462, PMID: 41516417).

3. Monocyte/Macrophage Pro-inflammatory Modules

• Lupus Immune Complex (IC) Activation: Immune complexes (e.g., snRNP/anti-snRNP) activate monocytes via TLR7/8 and the NLRP3 inflammasome, leading to the release of IL-1β and IL-18 (PMID: 41648138).
• S100+ Pro-inflammatory Subsets: Single-cell profiling identifies an expansion of S100A8/A9-expressing monocytes in the blood and kidneys of patients with lupus nephritis (LN). These cells utilize the ETS2 transcription factor as a master regulator of their inflammatory program (PMID: 41648138).

4. Complement and Clearance Defects

• Early Pathway Deficiency: Homozygous deficiencies in C1Q, C1R/C1S, C4, and C2 are strongly associated with monogenic SLE due to the ineffective opsonization of apoptotic cells (PMID: 38420886).
• Synaptic Stripping: In neuropsychiatric SLE (NPSLE), C1q coordinates with microglia to drive the destruction of synaptic terminals (PMID: 38420886).

Prioritized Causal Experiments to Validate Mechanism

To move beyond associative studies, the following experimental strategies are prioritized:

1. Perturbation and Genetic Engineering

• Keratinocyte-Specific Deletion: Use inducible models (e.g., Pparg deletion in basal layer keratinocytes) to prove that epithelial dysfunction alone is sufficient to trigger systemic IFN-β production and break immune tolerance (Direct; PMID: 41641005).
• CRISPR/Cas9 Validation: Prioritize editing of the ETS2 super-enhancer in human macrophages to confirm its necessity in driving the pro-inflammatory "lupus IC signature" (Derived; PMID: 41648138, PMID: 41675494).
• TLR7 GoF Modeling: Validate that the TLR7 Y264H mutation directly causes the differentiation of B cells into pathogenic ABCs using CRISPR-engineered mouse models (Direct; PMID: 38420886).

2. Single-Cell and Spatial Profiling

• Spatial Interactomics: Employ spatial transcriptomics to map the MIF-(CD74-CXCR4) interaction hub in LN kidney biopsies. This identifies how tubular epithelial cells recruit CD74+ B cells and T cells into the renal niche (Direct; PMID: 41490945).
• scBCR-seq Trajectory Analysis: Use paired scRNA-seq and B-cell receptor sequencing to track the clonal evolution of autoreactive B cells from the peripheral blood into tissue-resident tertiary lymphoid structures (TLS) (Derived; PMID: 41597194, PMID: 41490945).

3. Multi-Omics Integration and Mendelian Randomization (MR)

• Bidirectional MR: Prioritize MR studies to disentangle the causal relationship between viral triggers (e.g., EBV EBNA-1 antibodies) and SLE risk, mitigating the confounding of reverse causation found in observational cohorts (Direct; PMID: 41496099).
• Oligoprotein Signature Validation: Use high-plex proteomics (e.g., Olink) to validate that peripheral "interferon scores" (MIRO scores) can predict incident SLE up to nine years before clinical diagnosis (Direct; PMID: 41593088).

4. Microbiota-Metabolite Axis Validation

• Fecal Microbiota Transplantation (FMT): Validate that Lactobacillus reuteri and its metabolite indole-3-acetic acid (IAA) causally drive NPSLE by activating the AHR/STAT3 pathway in hippocampal microglia, using FMT from patients into germ-free or antibiotic-depleted mice (Direct; PMID: 36792346).

Synthesis

Evidence consistently identifies the Type I IFN/TLR7/B-cell axis as the primary driver of SLE (PMID: 38420886, PMID: 41597194). While GWAS has identified over 300 loci, functional validation via scRNA-seq/spatial transcriptomics and keratinocyte-specific perturbation is necessary to confirm that localized epithelial and myeloid triggers propagate systemic organ damage (PMID: 39624492, PMID: 41641005). Future therapeutics, such as CAR-T cell therapy and JAK inhibitors, should be prioritized for patients exhibiting these specific molecular endotypes (PMID: 39343084, PMID: 41682782).

Evidence Quality: Strong (Multiple randomized trials and high-resolution single-cell/spatial studies).

Limitations: Most scRNA-seq studies in NPSLE are currently restricted to animal models due to the invasive nature of human brain/CSF sampling (PMID: 41608446). Diagnostic administrative data in large biobanks may be prone to misclassification compared to strict ACR/EULAR criteria (PMID: 41593088).